Interleukin-33 (IL-33) is a pro-inflammatory cytokine that plays a significant role in inflammatory diseases by activating immune cells to induce type 2 immune responses upon its release. Although IL-33 is known to be released during tissue damage, its exact release mechanism is not yet fully understood. Previously, we have shown that cleaved IL-33 can be detected in the plasma and epithelium of Ripk1 À/À neonates, which succumb to systemic inflammation driven by spontaneous receptor-interacting protein kinase-3 (RIPK3)-dependent necroptotic cell death, shortly after birth. Thus, we hypothesized that necroptosis, a RIPK3/mixed lineage kinase-like protein (MLKL)-dependent, caspase-independent cell death pathway controls IL-33 release. Here, we show that necroptosis directly induces the release of nuclear IL-33 in its full-length form. Unlike the necroptosis executioner protein, MLKL, which was released in its active phosphorylated form in extracellular vesicles, IL-33 was released directly into the supernatant. Importantly, full-length IL-33 released in response to necroptosis was found to be bioactive, as it was able to activate basophils and eosinophils. Finally, the human and murine necroptosis inhibitor, GW806742X, blocked necroptosis and IL-33 release in vitro and reduced eosinophilia in Aspergillus fumigatus extract-induced asthma in vivo, an allergic inflammation model that is highly dependent on IL-33. Collectively, these data establish for the first time, necroptosis as a direct mechanism for IL-33 release, a finding that may have major implications in type 2 immune responses.
Introduction
Interleukin-33 (IL-33), a pro-inflammatory cytokine belonging to the IL-1 superfamily [1] , is expressed in epithelial cells exposed to the environment, such as in the skin, the gut, and respiratory tract, as well as in endothelial cells and fibroblasts [2, 3] . The N-terminal region of IL-33 contains a nuclear binding domain, hence its constitutive expression is in the nuclei of these cells, where it binds to the histone heterodimer H2A-H2B at the nucleosome surface [4] . The nuclear function of IL-33 is still a matter of debate and it was recently shown to have no effect on global gene expression in an IL-33-stably expressing esophageal epithelial cell line [5] . Upon binding to its surface receptor, ST2, IL-33 signals via myeloid differentiation primary response 88 to activate NF-jB and mitogenactivated protein kinases. This consequently promotes type 2 cytokine secretion and the survival and proliferation of ST2 + myeloid cells, such as eosinophils, basophils, and mast cell, as well as lymphoid cells, including Tregs, T H 2 cells, and type 2 innate lymphoid cells [6] . Transgenic (tg) mice lacking the N-terminal nuclear domain of IL-33 have elevated serum IL-33 levels and ST2-dependent lethal inflammation, highlighting the potency of extracellular IL-33 and the importance of its nuclear sequestration at baseline [7] .
Unlike other IL-1 family members, full-length IL-33 is biologically active but is tightly regulated at several cleavage sites. The apoptotic caspases, caspase-3 and caspase-7, process IL-33 to an inactive product by cleaving its C-terminal IL-1-like domain (112-270). The inflammatory caspases, caspase-1, -4, and -5, hardly possess this ability [8, 9] . Shown biochemically, cleavage by neutrophil- [10] and mast cell- [11] proteases, such as neutrophil elastase, cathepsin G, chymase, and tryptase, results in an IL-33 hyperactive form. However, supernatant (S/N) containing granule proteases from activated neutrophils was recently shown to suppress IL-33 activity overall, as cleavage by proteinase 3 opposes cathepsin G and elastasemediated hyperactivation [12] . Proteases from environmental allergens can also cleave IL-33 into mature products that exhibit increased potency in vitro and in vivo [13] . Lastly, IL-33 can undergo additional regulatory extracellular modification by cysteine oxidation [14] or by binding to its decoy receptor, soluble ST2 (sST2) [15] , that abolishes its activity.
Interleukin-33 is a crucial actor in lung inflammation. sST2 and IL-33 levels in serum and induced sputum are higher in young asthmatic patients compared with healthy controls [16, 17] , as well as in chronic obstructive pulmonary disease (COPD) patients [18] .
IL-33 and its receptor are identified as major susceptibility loci for asthma in several genome-wide association studies [19] . IL-33-deficient mice studies emphasize the essential role of IL-33 in inducing IL-13, mucus overproduction [1, 20] , and lung disease following viral infection [21] . When administered directly to mouse lung, cleaved IL-33 induces eosinophilic inflammation and airway hyperresponsiveness [22, 23] .
Because IL-33 lacks a secretion signal sequence, its release mechanism remains unknown. In vitro, IL-33 was shown to be released from endothelial cells following freeze-thaw cycles and exposure to nonionic detergents, such as Nonidet P-40 and Triton X-100 [9] . Endogenous IL-33 was released from THP-1 cells, bone marrow-derived macrophages and bone marrow dendritic cells upon exposure to hydrogen peroxide, sodium azide, streptolysin O, and high doses of daunorubicin, while hardly secreted upon apoptosis induction [8] . IL-33 was detected in the S/N of fibroblast-like synoviocytes from rheumatoid arthritis patients cultured with IL-1b and tumor necrosis factor-a (TNF-a) and treated with Nonidet P-40 [24] . IL-33 chromatin binding was recently reported to slow release during cryoshock-or calcium ionophore A23187-induced necrosis in an esophageal epithelial cell line [5] . Alum-induced cellular necrosis results in elevated levels of IL-33 following intraperitoneal injection (IP) in vivo [25] . In addition, IL-33 is released from cultured endothelial cells following scraping, which mimics mechanical forces in vivo [9] . Biomechanical stress by biaxial stretch induces IL-33 secretion from IL-33-stably expressing fibroblasts and primary human skin fibroblasts [26] . All together, these experiments suggest that IL-33 may be released upon accidental cell death (necrosis).
Necroptosis, which was originally defined as a receptor-interacting protein kinase 1 (RIPK1)-dependent and caspase-independent form of cell death [27] , was later discovered to require RIPK3 and the mixed lineage kinase-domain like pseudokinase MLKL [28] [29] [30] . Hence, necroptosis is best defined as RIPK3/MLKLdependent, caspase-independent, inflammatory cell death [31] . While various stimuli can activate necroptosis by engaging death receptors, Toll-like receptors (TLRs) or intracellular receptors, they all require caspase-8 inhibition to prevent cleavage and inactivation of RIPK3 [32] [33] [34] . When caspase-8 activity is blocked by different viral or bacterial pathogens, or spontaneously in specific settings, extra-or intracellular signals trigger phosphorylation of RIPK3, which leads to aggregation of MLKL and its phosphorylation by RIPK3 [28, [35] [36] [37] . Phosphorylated MLKL (pMLKL) then translocates to the plasma membrane and compromises its integrity, inducing necroptosis [38] [39] [40] . Thus, necroptosis can be prevented by genetic depletion of RIPK3 and MLKL, or chemically inhibited by necrostatin-1s (Nec-1s) [41, 42] , GSK2399872A (GSK'872) [30] , and necrosulfonamide (NSA) [37] or GW806742X (GW80) [43] , which inhibit RIPK1, RIPK3, and MLKL, respectively. Unlike apoptosis, necroptosis is characterized by cell swelling, membrane permeabilization and a leakage of cytoplasmic content resulting in the release of dangerassociated molecular patterns (DAMPs) that may act as alarmins to induce inflammation [31, [44] [45] [46] . Cleaved IL-33, which was detected in the plasma of mice lacking RIPK1, was suggested to be one such alarmin. Ripk1 À/À mice undergo spontaneous apoptosis and necroptosis and die at birth due to systemic inflammation. However, extracellular IL-33 is still found in the skin and plasma of Ripk1 À/À Casp8 À/À mice, which, although protected from apoptotic cell death, still die from lethal inflammation. On the other hand, Ripk1
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À/À mice, which are protected from necroptosis, do not release IL-33, suggesting necroptosis as a potential release mechanism for bioactive IL-33 [44] . Many features of IL-33 biology make it an important alarmin for further study: the poorly defined release mechanism, the unique nuclear localization in barrier tissues, its suppression by apoptosis and conversely release in response to trauma and its multiple cleavage sites controlling its extracellular activity. Here, we aimed to define the direct role of necroptosis in IL-33 release. We show that full-length and, importantly, bioactive IL-33 is released directly from necroptotic, but not apoptotic, cells. We report that the necroptosis inhibitor GW80 inhibits necroptosis and IL-33 release in vitro and attenuates lung inflammation in vivo in an IL-33-dependent Aspergillus fumigatus extract-induced asthma model. Thus, we propose that necroptosis is a direct IL-33 release mechanism, implying that IL-33 is a necroptotic DAMP. Furthermore, our in vivo results suggest a clear role for necroptotic release of IL-33 in mediating lung pathology in asthma, offering a new avenue for therapeutic intervention.
Results

Necroptosis induces IL-33 release
To investigate the direct role of necroptosis in IL-33 release, we established two in vitro systems of stably expressing IL-33-GFP cell lines that are sensitive to both apoptosis and necroptosis: (a) HaCaT -a human keratinocyte cell line; and (b) L929 -a murine fibrosarcoma cell line (Fig. 1A,B) . To enable an endogenous IL-33 localization pattern, a self-cleaving peptide (T2A) was inserted between the IL-33 and GFP sequences. Immunofluorescence staining confirmed the nuclear localization of IL-33 in the infected cells, as reported for the endogenous cytokine (Fig. 1C,D) [4, 47] . As expected, IL-33-expressing HaCaT cells were sensitive to apoptosis, induced by TNF-a and a second mitochondrial-derived activator of caspases (SMAC) mimetic (TS), and necroptosis, induced by TNF-a, a SMAC mimetic, and the pan-caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (z-VAD-fmk; TSZ; Fig. 2A ) [48] . IL-33 was detected in the S/N of necroptotic, but not apoptotic, HaCaT cells in a time-dependent manner following treatment (Fig. 2B,C) . L929 cells treated with apoptotic stimuli (TS), are known to present a mixed phenotype of both apoptotic and necroptotic cell death, without the need for exogenous caspase inhibition [49] . In this setting, L929 cells exhibited slower death kinetics ( We have previously reported that an early stage in necroptotic cell death includes phosphatidylserine exposure and release of extracellular vesicles (ECVs) that contain pMLKL [48] . As pMLKL detection in the necroptotic S/N correlated with IL-33 detection, we decided to examine the possibility that IL-33 is being released in ECVs. However, ECVs separation demonstrated a distinct localization pattern for pMLKL and IL-33. Full-length IL-33 was detected in the soluble fraction of necroptotic cell S/N, while pMLKL was detected in the ECVs fractions 7-9 ( Fig. 3 ).
Necroptotic IL-33 is biologically active
We next investigated whether the IL-33 released by necroptosis is biologically active using two different models based on published systems [11, 50] : (a) KU812, a human basophilic cell line, which secretes IL-5 in response to recombinant IL-33 in a dose-dependent manner (Fig. 4A) ; and (b) primary eosinophils, isolated from the peritoneal fluid of IL-5 tg mice, which secrete IL-6 in response to recombinant IL-33 in a dose-dependent manner (Fig. 4B ). Since these cells are being exposed to apoptotic and necroptotic stimuli (e.g., TS and TSZ) left in the S/N from the treated IL-33-expressing cells, we tested their direct sensitivity to these death inducers. KU812 cells and eosinophils demonstrated similar cell death kinetics in response to both apoptotic and necroptotic stimuli (Fig. 4C,D) . Thus, to control for this direct effect, and for any other DAMPs that may be released during our treatment, we compared the ability of apoptotic and necroptotic IL-33-GFP HaCaT cells to induce IL-5 (KU812) or IL-6 (primary IL-5tg eosinophils) with that of apoptotic and necroptotic GFP-only HaCaT. Following an overnight co-culture, S/Ns were collected and tested for IL-5 or IL-6 as a read-out of IL-33 activity (Fig. 4E ). KU812 cells that were co-cultured with IL-33-GFP necroptotic cells secreted significantly higher levels of IL-5 compared to GFP-only necroptotic cells, or IL-33-GFP apoptotic cells (Fig. 4F ). Primary IL-5tg eosinophils exhibited a similar pattern for IL-6 release (Fig. 4G) . Therefore, we conclude that the full-length IL-33 released during necroptosis retains its biological activity.
GW806742X, a murine MLKL inhibitor, reduces lung eosinophilia in Aspergillus extract-induced asthmatic mice
Among patients with persistent asthma requiring specialist referral, 20-25% have a skin-test reactivity to Aspergillus or other fungi [51, 52] . Asthmatic children with a positive IgE or skin prick test response to A. fumigatus, Alternaria alternata, or Cladosporium herbarum, have an earlier onset of symptoms with higher total IgE and airway IL-33 [53] . Therapeutically, targeting the IL-33 receptor, ST2, significantly reduces airway inflammation, airway remodeling, and hyperactivity in a mouse model of Aspergillus-induced asthma [54] . ST2-deficient mice also demonstrate reduced airway hyperactivity in response to Asperamide-B, an Aspergillus glycosphingolipid [55] .
Our in vitro data raised the hypothesis that necroptosis-induced IL-33 release may contribute to the development of allergic airway disease. To this end, we examined the role of necroptosis in an A. fumigatus extract (Asp.)-induced allergic airway inflammation, using a recently discovered murine necroptosis inhibitor, GW80 [43, 56, 57] . Treatment with GW80 resulted in delayed cell death kinetics for TSZ-, but not TS-, treated IL-33-GFP-expressing L929 or HaCaT cells, thus confirming its ability to inhibit necroptotic cell death in vitro (Fig. 5A,C) . In agreement with our earlier results showing necroptotic release of IL-33, GW80 prevented release of pMLKL and IL-33 into the S/N and retained IL-33 in the cell lysate of TSZ-, but not TS-, treated cells (Fig. 5B,D) .Finally, mice treated with GW80 1 h prior to Asp.-extract challenge exhibited a decrease in recruitment of eosinophils and CD4 + T cells to the bronchoalveolar space, while neutrophil recruitment was not affected (Fig. 6B-E) . GW80 treatment also decreased pMLKL in the bronchoalveolar lavage (BAL) fluid as detected by western blot (Fig. 6G) . In correlation, low levels of cleaved IL-33 were detected in the BAL fluid of the Asp.-challenged mice, supporting our hypothesis (Fig. 6G) . Serum IgE levels were lower in the GW80-treated mice (Fig. 6F) . In addition, airway inflammation and lung eosinophil infiltration were reduced in response to GW80 treatment (Fig. 6H-K) .
In summary, the ability of the necroptotic inhibitor GW80 to attenuate pathology in an IL-33-dependent Asp.-induced asthma model suggests a role for necroptosis in IL-33 release in asthma. However, future studies will clarify whether necroptosis effects asthma in an IL-33-dependant or independent manner.
Discussion
Interleukin-33 plays an important role in various inflammatory diseases, such as asthma, allergic skin diseases, obesity, inflammatory bowel diseases, arthritis, myocardial infarction, infections, and cancer [58] . Inhibition of disease in ST2-deficient mice and in mice treated with IL-33-neutralizing antibodies emphasizes that this cytokine has an important extracellular role following its release. In addition, numerous modifications can regulate full-length IL-33 in the extracellular environment to modify its bioactivity. These modifications include oxidation, cleavage, and rapid degradation following cleavage [13] . Yet, the mechanisms for IL-33 release in physiological and pathological environment are poorly understood [59] .
Herein, we elucidate, for the first time to our knowledge, the direct role of necroptosis in IL-33 release. We show that full-length, bioactive IL-33 is released during necroptotic, but not apoptotic, cell death. These findings distinguish this necroptotic release from the apoptotic modification, in which IL-33 is cleaved intracellularly by apoptotic caspases to an inactive product [8] . Altogether, these data support a model where IL-33, similar to the other nuclear IL-1 family members, functions as a canonical DAMP at the intersection of cell death and inflammation [60] . Il33 mRNA encodes a protein of 270 residues in human and 266 residues in mouse, with mass of 30 and 29.9 kDa, respectively. The human gene is located on chromosome 9p24.1, while the murine gene is found on the syntenic chromosome 19qC1. Human and mouse IL-33 are 55% identical at the amino acid level, and are both the closet relatives of IL-18 of all IL-1 family members [1] . The human and murine genes share similar organization with seven exons which are highly conserved by size. Alignment of these two proteins revealed that they are both composed of two evolutionary conserved regions separated by different linker region, one of which is the chromatin binding motif in the Nterminal domain [61] . Crystal structure studies revealed that the surface charge complementarity between IL-33 and its receptor, ST2, is critical for specific binding [62] . Murine lymphoid cells are being as effectively activated by recombinant human IL-33 as by the recombinant mouse IL-33 [58] . Here, for the first time to our knowledge, we presented the complementary phenomenon, in which the mouse IL-33 activates human basophils. Of note, mouse IL-33 was found to undergo a rapid degradation following cleavage while the human cleaved product remains stable [13] . It should be noted that another mechanism for IL-33 release has been reported. Human tracheobronchial epithelial cells cultured from COPD patients [18] , as well as corneal epithelial cells [63] , astrocytes, and glial cells [64] , stimulated with TLR ligands were shown to release IL-33 via an ATP-dependent, noncytotoxic mechanism. IL-33 release from bronchial cells exposed to A. alternata allergenic extract was shown to be dependent on ATP-mediated Ca 2+ increase [65] . Yet, A. alternata treatment was also shown to increase necrosis of na€ ıve murine lung cells in a similar IL-33-release system, arguing that necroptosis may be responsible for its regulated release [66] .
Interleukin-33 was first suspected to be a necroptotic DAMP, as mice lacking caspase-8 in keratinocytes develop an atopic dermatitis-like disease and upregulate Il33 gene expression [67, 68] . Similarly, RIPK3-induced necroptosis increased Il33 gene expression in intestinal epithelial cells in vitro [69] . Nec-1s downregulates liver IL-33 protein expression in Listeria monocytogenes-infected mice [70] , and attenuates D-Galactosamine/Lipopolysaccharideinduced hepatocellular damage and serum IL-33 [71] . However, due to its nuclear translocation sequence, IL-33 expression does not necessarily correlate with its release.
In summary, our findings that necroptotic cell death can release bioactive IL-33, and that necroptosis exacerbates allergic inflammation in an Aspergillus-induced asthma model (a known IL-33 disease model) underline the possibility that necroptosis facilitates inflammation in IL-33-related pathologies. Our results point to the need to study the role of MLKL, RIPK3, and RIPK1 in IL-33-related diseases, especially as pharmacological inhibitors for necroptosis enter clinical development.
Materials and methods
Reagents
Recombinant human TNFa was purchased from PeproTech (Rocky Hill, NJ, USA). The SMAC mimetics, 3,3 0 -
L-prolinamide (AZD 5582) dihydrochloride and the MLKL inhibitor, NSA, were purchased from Tocris Bioscience (Bristol, UK). The pan-caspase inhibitor, Z-VAD-fmk (zVAD), the RIPK1 inhibitor, Nec-1s, and the RIP3 inhibitor, GSK'872, were purchased from Calbiochem (Merck Millipore, Danvers, MA, USA). The necroptosis inhibitor GW80 was purchased from Sigma-Aldrich (Merck Millipore). Halt protease and the phosphatase inhibitors cocktail EDTA free was purchased from Pierce Biotechnology (Thermo Fisher Scientific, Waltham, MA, USA). Commercial antibodies were used at 1 : 1000 dilution and pur- 
Cell culture
The L929 murine fibrosarcoma cell line and the HaCaT human keratinocyte cell line were cultured in Dulbecco's modification of Eagle (DMEM; Biological Industries, Beit Haemek, Israel), and the KU812 human basophil cell line was cultured in Roswell Park Memorial Institute-1649 (RPMI; Biological industries), both supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 1% HEPES at 37°C in a humidified 5% CO 2 atmosphere. All three reagents were purchased from Gibco (Thermo Fisher Scientific). All cell lines were tested for mycoplasma before use.
Generating of GFP-or IL-33-GFP-stably expressing cells lines
For the GFP-expressing plasmid, pLL3.7-CMV-T2A-EGFP vector was provided by the Tel Aviv University Vector Core (Tel Aviv, Israel). For the IL-33-GFP-expressing plasmid to be transduced, the cDNA for the murine IL-33 (NM_133775) was amplified from pET45b-murine IL-33 plasmid that was kindly given by Prof. Seamus Martin, using the following primers: forward, TCCGCTAGCGC CACCATGAGACCTAGAATGAAGTATTCCAACTCCA AG and reverse, TGGGGATCCGATTTTCGAGAGCT TAAACATAATATTGTTGCAGC. The insert was then restricted using Nhel and BamHI restriction enzymes (New England Biolabs, Ipswich, MA, USA), and was cloned into the restricted pLL3.7-CMV-T2A-EGFP using quick ligase (New England Biolabs) following the manufacturer's protocol, between the CMV promoter and the sequence for the T2A self-cleaving peptide. Sanger sequencing of the replaced restriction fragment was performed. Lentivirus was generated by transfecting HEK 293T cells with either pLL3.7-CMV-T2A-EGFP or pLL3.7-CMV-mIL-33-T2A-EGFP plasmids using lipofectamine 3000 reagent (Thermo Fisher Scientific) following the manufacturer's protocol. HaCaT and L929 cells were then transduced with the filtered S/N with the addition of polybrene (8 lgÁlL
À1
). A few h later, the cells were washed and the S/N was replaced. GFP-positive cells were sorted (FACSAria, BD Biosciences, San Jose, CA, USA) 3 weeks later.
Immunofluorescence GFP-positive-HaCaT and L929 cells were grown on coverslips and fixed for 20 min in PBS containing 4% paraformaldehyde. The coverslips were then washed for three times and cells were permeabilized with 0.1% Triton X-100 in PBS and then blocked with 1% bovine serum albumin in the permeabilization buffer for 1 h. Next, the cells were incubated at 4°C with polyclonal goat anti-mouse IL-33 antibody (1 : 50, AF3626, R&D). After overnight incubation, cells were incubated at room temperature with Alexa Flour 680-conjugated donkey anti-goat secondary antibody (1 : 500), for 1 h. Hoechst 33342 (1 : 1000, Calbiochem; Merck Millipore) was added for 5 min to stain cell nuclei. Cells were visualized using fluorescence microscopy (EVOS Fl Auto; Thermo Fisher Scientific). 
Cell death stimuli
Live imaging assay
Plates with stimulated cells were placed on the Incucyte-ZOOM and 1 or 9 images per well were recorded for the 96-or 24-well plates, respectively, every 10-30 min. Data were analyzed using the IncucyteZoom2016B analysis software (Essen BioScience, Inc., Ann Arbor, MI, USA) and exported to GRAPHPAD PRISM software (GraphPad Software, San Diego, CA, USA). Normalization was then performed according to the maximal PI-positive object count to generate the frequency of dead cells.
Western blots
Stimulated cells and their S/Ns were collected at the indicated time points. S/N was first centrifuged for 5 min at 400 g to pellet cellular debris. Cells were then lysed by the addition of RIPA buffer in the presence of the HALT protease and phosphatase inhibitors cocktail for 15 min at 4°C. S/Ns were concentrated by a methanol-chloroform protein precipitation method, as recently described [72] . Samples were mixed with SDS/PAGE loading buffer, boiled for 5 min, and loaded into SDS/PAGE precast gels (BIO-RAD, Rishon LeTsiyon, Israel) for western blot analysis. Proteins were transferred onto 0.2 lm nitrocellulose membrane using the Trans-Blot Turbo Transfer system (BIO-RAD). Membranes were blocked with 5% skim milk in TBS-T (20 mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween-20) for 1 h and probed overnight with the primary antibodies, as indicated above, diluted in 5% skin milk in TBS-T, followed by washes and addition of HRP-conjugated secondary antibodies (1 : 5000 in 5% skin milk in TBS-T) for 1 h. Images were taken using Odyssey Fc system (LI-COR Biosciences, Lincoln, NE, USA) and analyzed using IMAGESTUDIO ANALYSIS software (LI-COR Biosciences).
Fractionation of supernatant proteins
Supernatants were collected at the indicated time points. S/ Ns were first centrifuged for 5 min at 400 g to remove cellular debris. Protein fractions were isolated by size exclusion chromatography using the qEV commercial kit (Izon Sciences, Medford, MA, USA) according to the manufacturer's instructions. Briefly, 10 mL of S/N from stimulated cells was concentrated into 500 lL using 3KD Amicon Ultra 15 mL Centrifugal filters (Merck Millipore). Every three consecutive fractions (500 lL each) were fused and concentrated by methanol-chloroform protein precipitation method, as recently described [72] for western blot analysis. Extracellular vesicles are isolated in fractions 7-9, while free proteins are in fractions 13-25.
Primary IL-5 tg eosinophil isolation for bioactivity assay
Peritoneal lavage of CD3-IL-5 tg mice was performed by flushing the peritoneal cavity with 5 mL PBS. Peritoneal fluid was centrifuged for 5 min at 400 g and the cells were then enriched for eosinophils using negative selection with magnetic beads (Dynabeads; Invitrogen, Thermo Fisher Scientific) linked to anti-mouse pan-B (B220) and antimouse pan-T (CD90.2) antibodies, according to the manufacturer's instructions.
Bioactivity assay
To confirm the bioactivity system, 1 ), according to the manufacturer's protocol.
Mice
Female 6-7-week-old C57BL/6J-RccHsd mice were obtained from Envigo RMS (Jerusalem, Israel). CD3-IL-5-transgenic (NJ.1638, Il5
Tg ) mice were kindly provided by J.
Lee (Mayo Clinic, Scottsdale, AZ, USA) and grown inhouse. All experiments were reviewed and approved by the Animal Care Committee of Tel Aviv University (Number 01-16-094) and were performed according to its regulations and guidelines regarding the care and use of animals for experimental procedures. All experiments were conducted in the specific pathogen-free facility of Tel Aviv University.
Allergen sensitization and challenge
Asthma was induced by sensitizing mice by IP of 20 lg of Asp. (Greer Laboratories, Lenoir, NC, USA) in 200 lL saline containing Alum (Imject Alum Adjuvant, 77161, Thermo Scientific) in a 1 : 1 ratio on days 0 and 7, using a 25 G needle. The sensitization mix was mixed for 30 min prior to use to ensure efficient antigen absorption by the Alum particles. For challenge, on days 18, 19, and 20, mice were anesthetized by isoflurane inhalation, and 10 lg Asp. in 50 lL of saline was applied to the nasal cavity using a micropipette while the mice were held in the supine position. Mice were held upright for 5 s after each administration. Where indicated, GW80, a necroptosis inhibitor (100 lM in 50 lL saline) was also given intranasally 1 h prior to challenge. Mice were bled and killed 24 h after the last challenge, and BAL was performed by washing the lungs three times with 500 lL saline. Following centrifugation, cells were assessed by flow cytometry.
Flow cytometry
Flow cytometric analysis of BAL cells was conducted using the following antibodies: anti-CD4 (RM-4; Biogems, 
Histology and immunohistochemistry
The left lung was fixed in 4% paraformaldehyde in PBS, embedded in paraffin, and cut into 5-lm sections. Sections were deparaffinized and stained with hematoxylin and eosin (H&E). The inflammatory state of the lungs was evaluated by two independent researchers by 1-5 scoring of cellular infiltration at 19 magnification and peribronchial inflammation (assessed by peribronchial infiltration and mucus accumulation) at 109 magnification. Some of the sections were deparaffinized and immunostained with anti-major basic protein (anti-MBP) antibody (from J. Lee's, Mayo clinic) by the common immunohistochemistry procedure [73] . Eosinophils (MBP-labeled cells) were acquired and counted using IMAGEJ (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis
Statistical analysis was performed using GRAPHPAD PRISM 7 software.
